Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 8/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | SHBG | P04278 | 4/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | PGR | P06401 | 3/20 | 0.67 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.67 |
| ▸ | AR | P10275 | 3/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | SNCA | P37840 | 3/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.67 |
| ▸ | STS | P08842 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978824 | 1.00 | CYP2D6 (0.72) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL928512 | 0.86 | CYP2D6 (0.72) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL7993008 | 0.86 | CYP2D6 (0.72) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL13123065 | 0.86 | CYP2D6 (0.72) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL3664511 | 0.86 | CYP2D6 (0.54) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL12418986 | 0.83 | HSD17B1 (0.68) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL2289060 | 0.81 | HSD17B1 (0.69) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL12379628 | 0.81 | HSD17B1 (0.69) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL2289611 | 0.81 | HSD17B1 (0.69) | CYP2D6ESR1ESR2LMNAHSD17B10 | |
| SCHEMBL5675177 | 0.81 | ESR1 (0.64) | CYP2D6ESR1ESR2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040223983-A1 | Pharmaceutical preparations, use of these preparations and process for increasing the biovailability of pharmaceutical substances to be administered perorally | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-11-11 | — | — | US | claimed |
| US-8003783-B2 | Steroid 17 beta -hydroxysteroid dehydrogenase inhibitors substituted with one or more oxime groups, especially aromatase inhibitors used in the treatment of endocrine-dependent tumors, especially breast cancer | STERIX LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| EP-2336146-A1 | 17beta-hydroxysteroid dehydrogenase inhibitors | Sterix Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-7732493-B2 | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
| EP-1763534-B1 | NOVEL 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BAYER SCHERING PHARMA AG (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20080306164-A1 | NEW 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HILLISCH ALEXANDER | 2008-12-11 | — | — | US | disclosed |
| US-7435757-B2 | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | SCHERING AG (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7419972-B2 | 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 | SCHERING AG (DE) | 2008-09-02 | — | — | US | disclosed |
| EP-1771461-A2 | NOVEL 2-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONES USED IN THE FORM OF INHIBITORS OF 17BETA-HYDROXYSTEROIDDEHYDROGENASE OF TYPE 1 | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-04-11 | — | — | EP | disclosed |
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-05 | — | — | US | disclosed |
| US-5550107-A | Combination therapy for the treatment of estrogen-sensitive disease | ENDORECHERCHE INC. (CA) | 1996-08-27 | — | — | US | disclosed |
| EP-0462189-B1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES | ENDORECHERCHE INC (CA) | 1995-09-27 | — | — | EP | disclosed |
| US-5395842-A | Inhibitors of sex steroids | ENDORECHERCHE INC. (CA) | 1995-03-07 | — | — | US | disclosed |
| US-5364847-A | Inhibitors of sex steroid biosynthesis and methods for their production and use | ENDORECHERCHE (CA) | 1994-11-15 | — | — | US | disclosed |
| EP-0615448-A1 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1994-09-21 | — | — | EP | disclosed |
| WO-1993010741-A2 | SEX STEROID ACTIVITY INHIBITORS | ENDORECHERCHE INC. (CA) | 1993-06-10 | — | — | WO | disclosed |
| US-5204337-A | Estrogen nucleus derivatives for use in inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| EP-0462189-A1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES. | ENDORECHERCHE INC (CA) | 1991-12-27 | — | — | EP | disclosed |
| WO-1990010462-A1 | COMBINATION THERAPY FOR TREATMENT OF ESTROGEN SENSITIVE DISEASES | ENDORECHERCHE INC. (CA) | 1990-09-20 | — | — | WO | disclosed |
| EP-0367576-A2 | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078114-A1 | COMBINATION THERAPY FOR ALZHEIMER'S DISEASE AND OTHER DISEASES | PSEN2, APP, PSEN1 | CYP2D6 3900/4885ESR1 208/4885ESR2 46/4885 |
| US-20080306164-A1 | NEW 2-SUBSTITUTED D-HOMO-ESTRA-1,3,5(10)-TRIENES AS INHIBITORS OF 17BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD17B11, HSD17B1, CYP19A1 | CYP2D6 80/4885ESR1 43/4885ESR2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.